SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-004490
Filing Date
2023-02-13
Accepted
2023-02-13 16:07:59
Documents
14
Period of Report
2023-02-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48746
2 ex2-1.htm EX-2.1 38454
3 ex10-1.htm EX-10.1 56784
  Complete submission text file 0001493152-23-004490.txt   334873

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ocx-20230207.xsd EX-101.SCH 3224
5 XBRL LABEL FILE ocx-20230207_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ocx-20230207_pre.xml EX-101.PRE 22358
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3461
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 23618411
SIC: 2835 In Vitro & In Vivo Diagnostic Substances